Abstract
Recently approved in Europe, Canada, and the United States, fast-acting insulin aspart (FIASP®) is a new rapid acting insulin. Approved for subcutaneous or IV injection use, there is little data available regarding the clinical utility of FIASP in insulin pumps. The article by Zijlstra and colleagues in this issue begins to close this gap by testing pump compatibility of FIASP in the clinic. Reporting on a small (37 subjects) and short (6 weeks) study looking at aspects of infusion set propensity for clogging and malfunction, no cases of infusion set plugging in either FIASP (25 subjects) or insulin aspart (12 subjects) were seen. Unexplained hyperglycemia and premature infusion set changes were more common with FIASP than with insulin aspart. This study demonstrated sufficient safety and efficacy of FIASP in the pump setting to pave the way for longer, larger and more definitive clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.